Biotech Giant, BioNTech, Proposed to Absorb Rival Firms
Breaking News: Biontech Takes Over Curevac in Groundbreaking Deal
Biontech, the renowned pharmaceutical giant from Mainz, has announced a game-changing move - acquiring its competitor Curevac based in Tübingen. Biontech co-founder Ugur Sahin revealed, "Our mission is to revolutionize cancer treatments and set new standards. This acquisition is a significant step towards achieving that goal."
Recently, Biontech skyrocketed to global fame during the COVID-19 pandemic due to its swift development of an mRNA vaccine. The partnership with pharmaceutical titan Pfizer propelled Biontech into the multi-billion dollar league. Although revenues have dipped in recent years, the Curevac deal doesn't seem like a financial obstacle for Biontech. The deal is set to be completed by the end of the year through a share exchange, valuing each Curevac share at roughly $5.46, totaling about €1.1 billion. Several major Curevac shareholders, including SAP co-founder Dietmar Hopp, have already agreed to the acquisition. Biontech anticipates backing from the German state bank KfW, which owns around 13% of Curevac's shares.
nd.Kompakt Daily, our popular newsletter, serves up the day's most compelling stories, curated by our dedicated team. Join us for free here.
Curevac's attempt to develop its COVID vaccine during the pandemic ended disastrously, plunging the company into an existential crisis. But news of the acquisition sent Curevac's stock soaring by nearly 40%, while Biontech's stock moderately dipped. Some analysts argue that the deal seems overpriced.
Biontech aims to "blend complementary abilities and technologies" to boost research, development, manufacturing, and commercialization of mRNA-based cancer immunotherapy candidates. However, experts also see a financial motive - both companies are locked in billion-dollar patent lawsuits in Germany and the US. While the legal situation is convoluted, analysts give Curevac a good chance in these disputes. A merger could resolve this issue.
The acquisition could also be strategic in the dynamic market for mRNA cancer therapies. Currently, there are only three leading players: Biontech, Curevac, and Moderna in the US. Biontech may aim to bar big pharma from entering the market by acquiring Curevac. Moreover, Moderna is ahead with financial backing from Merck, testing a skin cancer immunotherapy vaccine in late-stage clinical trials. Meanwhile, Biontech has forged a strategic partnership with Bristol-Myers Squibb to expedite the development of bispecific antibody candidate BNT327, targeting various tumor types.
The journey of mRNA cancer therapies began long ago. As early as the late 19th century, a US oncologist experimented with this. However, the focus shifted towards radiation therapy and chemotherapy due to initial success, both of which have severe side effects. Consequently, alternatives have been pursued for decades, including conventional vaccines. Initial clinical trials by Vienna-based researchers resulted in disappointing outcomes, but it was later discovered that vaccinated individuals had a remarkably higher chance of surviving cancer, as metastasis formation was inhibited.
Great expectations surround immune therapy in the scientific community. The big challenge lies in the variety of cancer types, making it difficult to develop a uniform vaccine. An advantage of mRNA technology could be its potential to create treatments customized for individual patients, leading to superior results, but potentially making them extremely expensive. This raises fears that entire population groups and regions across the globe may be left behind. In this light, the acquisition of Curevac by Biontech might just be another step in the complicated dance of innovation and affordability that characterizes the pharmaceutical industry.
In light of the acquisition, Biontech, aiming to revolutionize cancer treatments, intends to blend complementary abilities and technologies to develop mRNA-based cancer immunotherapy candidates, potentially creating treatments customized for individual patients. The acquisition could be a strategic move to bar big pharma from entering the market and resolve ongoing patent lawsuits with Curevac. This development further emphasizes the complex interplay of innovation, affordability, and medical-conditions like cancer in the pharmaceutical industry, as science pushes for health-and-wellness advancements while grappling with financial implications.
